‘Very exciting’ data: Bimekizumab superior to placebo in psoriatic arthritis

Patients with psoriatic arthritis treated with bimekizumab demonstrated improvements across joint and skin parameters compared with placebo, according to Phase 3 clinical trial data presented at the EULAR 2022 Congress.
“I am delighted to be able to present these very exciting Phase 3 data from the BE COMPLETE study of this inhibitor of both IL-17A and -F,” Joseph F. Merola, MD, of Brigham and Women’s Hospital and Harvard Medical School, told attendees.
Merola noted that the monoclonal IgG1 antibody bimekizumab (Bimzelx, UCB) has demonstrated safety and efficacy through 152

Patients with psoriatic arthritis treated with bimekizumab demonstrated improvements across joint and skin parameters compared with placebo, according to Phase 3 clinical trial data presented at the EULAR 2022 Congress.
“I am delighted to be able to present these very exciting Phase 3 data from the BE COMPLETE study of this inhibitor of both IL-17A and -F,” Joseph F. Merola, MD, of Brigham and Women’s Hospital and Harvard Medical School, told attendees.
Merola noted that the monoclonal IgG1 antibody bimekizumab (Bimzelx, UCB) has demonstrated safety and efficacy through 152